Synonyms: Bigumal® | chloroguanide | Paludrine®
proguanil is an approved drug (FDA (2000) in combination with atovaquone)
Compound class:
Synthetic organic
Comment: Proguanil is a biguanide derivative that, once administered, is converted to the active metabolite cycloguanil. It is an antimalarial drug, used in combination with atovaquone or with chloroquine.
The marketed formulations contain proguanil hydrochloride (PubChem CID 9570076). Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Proguanil is used in combination with atovaquone in both the treatment of uncomplicated malaria caused by P. falciparum and in malaria prophylaxis [1]. Proguanil is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). |
Mechanism Of Action and Pharmacodynamic Effects |
Cycloguanil, the active metabolite of proguanil, is an inhibitor of Plasmodium dihydrofolate reductase (DHFR). Proguanil has a different mechanism of action when used in combination with atovaquone, with the prodrug having synergistic activity, leading to enhanced collapse of the mitochondrial membrane potential [2]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |